1 research outputs found

    ΠŸΡ€Π΅Π΄ΠΈΠΊΡ‚ΠΎΡ€ΠΈ Π·Π° појава Π½Π° Π°Ρ‚Ρ€ΠΈΡ˜Π°Π»Π½Π° Ρ„ΠΈΠ±Ρ€ΠΈΠ»Π°Ρ†ΠΈΡ˜Π° ΠΏΠΎ Π°ΠΎΡ€Ρ‚ΠΎ-ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Π° бајпас ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΡ˜Π°

    Get PDF
    Atrial fibrillation (AF) is the most common type of arrhythmia following open heart surgery and it contributes to prolonged hospital stay, increased prevalence of thromboembolic complications and overall increased postoperative morbidity and mortality. The aim of this prospective observational follow-up study was to determine the incidence of postoperative atrial fibrillation (POAF) in patients undergoing coronary artery bypass surgery, to identify predisposing  risk factors for its occurrence in the immediate preoperative period and to assess its effect on the postoperative outcome in patients at the University Clinic for Cardiac Surgery in Skopje, North Macedonia. Material and methods: The study included patients at the University Clinic for Cardiac Surgery in Skopje, North Macedonia undergoing coronary artery bypass surgery. The experimental group included patients developing POAF, whereas the control group those who did not develop the primary outcome. All patients were followed up for a period of 30 days postoperatively. Results: POAF was registered in 38% of the patient population and more frequently in the elderly. Patients developing POAF had significantly higher left atrial volume index, as well as higher CHADS2-VASC2, HATCH and Euroscore I values. Average time to POAF occurrence was 48-72 hours postoperatively. There were death outcomes, thromboembolic events, longer hospital stay, need for antiarrhythmic and oral anticoagulant therapy in the POAF group. Conclusion: POAF significantly increases postoperative morbidity and mortality in patients undergoing coronary artery bypass surgery. Age, higher CHADS2-VASC2, HATCH and Euroscore I values and left atrial volume were found to be significant predictors of POAF after coronary artery bypass surgery.ΠΡ‚Ρ€ΠΈΡ˜Π°Π»Π½Π°Ρ‚Π° Ρ„ΠΈΠ±Ρ€ΠΈΠ»Π°Ρ†ΠΈΡ˜Π° (АЀ) прСтставува Π½Π°Ρ˜Ρ‡Π΅ΡΡ‚ΠΈΠΎΡ‚ Ρ‚ΠΈΠΏ Π½Π° Π°Ρ€ΠΈΡ‚ΠΌΠΈΡ˜Π° ΠΏΠΎ Ρ…ΠΈΡ€ΡƒΡ€Π³ΠΈΡ˜Π° Π½Π° ΠΎΡ‚Π²ΠΎΡ€Π΅Π½ΠΎ срцС ΠΈ истата придонСсува Π·Π° ΠΏΡ€ΠΎΠ»ΠΎΠ½Π³ΠΈΡ€Π°Π½ Π±ΠΎΠ»Π½ΠΈΡ‡ΠΊΠΈ ΠΏΡ€Π΅ΡΡ‚ΠΎΡ˜, Π·Π³ΠΎΠ»Π΅ΠΌΠ΅Π½Π° ΠΈΠ½Ρ†ΠΈΠ΄Π΅Π½Ρ†ΠΈΡ˜Π° Π½Π° тромбСмболиски ΠΊΠΎΠΌΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΠΈ ΠΈ ΠΎΠΏΡˆΡ‚ΠΎ Π·Π³ΠΎΠ»Π΅ΠΌΠ΅Π½ постопСративСн ΠΌΠΎΡ€Π±ΠΈΠ΄ΠΈΡ‚Π΅Ρ‚ ΠΈ ΠΌΠΎΡ€Ρ‚Π°Π»ΠΈΡ‚Π΅Ρ‚. Π¦Π΅Π»Ρ‚Π° Π½Π° ΠΎΠ²Π°Π° проспСктивна, опсСрвациска ΡΡ‚ΡƒΠ΄ΠΈΡ˜Π° Π½Π° слСдСњС бСшС Π΄Π° сС ΡƒΡ‚Π²Ρ€Π΄ΠΈ ΠΈΠ½Ρ†ΠΈΠ΄Π΅Π½Ρ†ΠΈΡ˜Π°Ρ‚Π° Π½Π° постопСративната Π°Ρ‚Ρ€ΠΈΡ˜Π°Π»Π½Π° Ρ„ΠΈΠ±Ρ€ΠΈΠ»Π°Ρ†ΠΈΡ˜Π° (ПОАЀ) кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ ΠΊΠΎΠΈ ΠΏΠΎΠ΄Π»Π΅Π³Π½ΡƒΠ²Π°Π°Ρ‚ Π½Π° Π°ΠΎΡ€Ρ‚ΠΎ-ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Π° бајпас ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΡ˜Π°, Π΄Π° сС ΠΎΡ‚ΠΊΡ€ΠΈΡ˜Π°Ρ‚ прСдиспонирачкитС Ρ€ΠΈΠ·ΠΈΠΊ-Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΈ Π·Π° појава Π½Π° Π°Ρ‚Ρ€ΠΈΡ˜Π°Π»Π½Π° Ρ„ΠΈΠ±Ρ€ΠΈΠ»Π°Ρ†ΠΈΡ˜Π° Π²ΠΎ нСпосрСдниот ΠΏΡ€Π΅Π΄ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π΅Π½ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄, ΠΊΠ°ΠΊΠΎ ΠΈ Π΄Π° сС Π΅Π²Π°Π»ΡƒΠΈΡ€Π° Π½Π΅Ρ˜Π·ΠΈΠ½ΠΈΠΎΡ‚ Π΅Ρ„Π΅ΠΊΡ‚ Π²Ρ€Π· постопСративниот исход Π½Π° ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€ΡˆΠΊΠΈΡ‚Π΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ Π½Π° ΠˆΠ—Π£ УнивСрзитСтска ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ° Π·Π° ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€Π³ΠΈΡ˜Π°Π²ΠΎΠ Π΅ΠΏΡƒΠ±Π»ΠΈΠΊΠ° Π‘Π΅Π²Π΅Ρ€Π½Π° МакСдонија. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΡ˜Π°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ: Π’ΠΎ ΠΎΠ²Π°Π° проспСктивна ΠΎΡ‚Π²ΠΎΡ€Π΅Π½Π° ΡΡ‚ΡƒΠ΄ΠΈΡ˜Π° Π½Π° слСдСњС Π±Π΅Π° Π²ΠΊΠ»ΡƒΡ‡Π΅Π½ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ хоспитализирани Π½Π° ΠˆΠ—Π£ УнивСрзитСтска ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ° Π·Π° ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€Π³ΠΈΡ˜Π°- БкопјС Π·Π° ΠΈΠ·Π²Π΅Π΄ΡƒΠ²Π°ΡšΠ΅ Π½Π° Π°ΠΎΡ€Ρ‚ΠΎ-ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Π° бајпас ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΡ˜Π°. Π’ΠΎ испитуваната Π³Ρ€ΡƒΠΏΠ° Π±Π΅Π° Π²ΠΊΠ»ΡƒΡ‡Π΅Π½ΠΈ ΠΎΠ½ΠΈΠ΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ,  ΠΊΠΎΠΈ Π²ΠΎ постопСративниот ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ Ρ€Π°Π·Π²ΠΈΡ˜Π° ПОАЀ, Π΄ΠΎΠ΄Π΅ΠΊΠ° Π²ΠΎ ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»Π½Π°Ρ‚Π° Π³Ρ€ΡƒΠΏΠ° Π±Π΅Π° Π²ΠΊΠ»ΡƒΡ‡Π΅Π½ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ ΠΊΠΎΠΈ Π½Π΅ Ρ€Π°Π·Π²ΠΈΡ˜Π° ПОАЀ. ΠŸΠΎΡΡ‚ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ Π±Π΅Π° слСдСни Π²ΠΎ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ ΠΎΠ΄ 30 Π΄Π΅Π½Π° ΠΎΠ΄ ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€ΡˆΠΊΠ°Ρ‚Π° ΠΈΠ½Ρ‚Π΅Ρ€Π²Π΅Π½Ρ†ΠΈΡ˜Π°. Π Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ: ПОАЀ бСшС рСгистрирана кај 38% ΠΎΠ΄ испитаницитС ΠΈ Ρ‚ΠΎΠ° почСсто кај повозрасната Π³Ρ€ΡƒΠΏΠ° испитаници. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ со ПОАЀ ΠΈΠΌΠ°Π° Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»Π½ΠΎ повисока врСдност Π½Π° индСксираниот Π²ΠΎΠ»ΡƒΠΌΠ΅Π½ Π½Π° Π»Π΅Π²Π°Ρ‚Π° ΠΏΡ€Π΅Ρ‚ΠΊΠΎΠΌΠΎΡ€Π°, ΠΊΠ°ΠΊΠΎ ΠΈ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»Π½ΠΎ повисока врСдност Π½Π° CHADS2-VASC2, HATCH ΠΈ Euroscore скоровитС,Π²ΠΎ однос Π½Π° Π³Ρ€ΡƒΠΏΠ°Ρ‚Π° Π±Π΅Π· ПОАЀ. ΠŸΡ€ΠΎΡΠ΅Ρ‡Π½ΠΎΡ‚ΠΎ Π²Ρ€Π΅ΠΌΠ΅ Π½Π° појава Π½Π° ПОАЀ бСшС 48-72 часа ΠΎΠ΄ Ρ…ΠΈΡ€ΡƒΡ€ΡˆΠΊΠ°Ρ‚Π° ΠΈΠ½Ρ‚Π΅Ρ€Π²Π΅Π½Ρ†ΠΈΡ˜Π°. Π’ΠΎ Π³Ρ€ΡƒΠΏΠ°Ρ‚Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ со ПОАЀ Π±Π΅Π· Π·Π°Π±Π΅Π»Π΅ΠΆΠ°Π½ΠΈ смртни случаи, ΠΊΠ°ΠΊΠΎ ΠΈ тромбоСмболиски ΠΊΠΎΠΌΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΠΈ, ΠΎΠ΄ Ρ‚ΠΈΠΏΠΎΡ‚ Π½Π° исхСмичСн ΠΌΠΎΠ·ΠΎΡ‡Π΅Π½ ΡƒΠ΄Π°Ρ€ ΠΈ ΠΎΠ²ΠΈΠ΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ ΠΈΠΌΠ°Π° ΠΏΠΎΠ΄ΠΎΠ»Π³ Π±ΠΎΠ»Π½ΠΈΡ‡ΠΊΠΈ ΠΏΡ€Π΅ΡΡ‚ΠΎΡ˜ ΠΈ ΠΏΠΎΡ‚Ρ€Π΅Π±Π° ΠΎΠ΄ Π°Π½Ρ‚ΠΈΠ°Ρ€ΠΈΡ‚ΠΌΠΈΡ‡Π½Π° Ρ‚Π΅Ρ€Π°ΠΏΠΈΡ˜Π° ΠΈ ΠΎΡ€Π°Π»Π½Π° Π°Π½Ρ‚ΠΈΠΊΠΎΠ°Π³ΡƒΠ»Π°Π½Ρ‚Π½Π° Ρ‚Π΅Ρ€Π°ΠΏΠΈΡ˜Π° (ОАК). Π—Π°ΠΊΠ»ΡƒΡ‡ΠΎΠΊ: ПОАЀ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»Π½ΠΎ Π³ΠΎ Π²Π»ΠΎΡˆΡƒΠ²Π° ΠΌΠΎΡ€Π±ΠΈΠ΄ΠΈΡ‚Π΅Ρ‚ΠΎΡ‚ ΠΈ ΠΌΠΎΡ€Ρ‚Π°Π»ΠΈΡ‚Π΅Ρ‚ΠΎΡ‚ кај ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€ΡˆΠΊΠΈΡ‚Π΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ. Возраста, високата врСдност Π½Π° CHADS2-VASC2, HATCH ΠΈ Euroscore, ΠΊΠ°ΠΊΠΎ ΠΈ Π²ΠΎΠ»ΡƒΠΌΠ΅Π½ΠΎΡ‚ Π½Π° Π»Π΅Π²Π°Ρ‚Π° ΠΏΡ€Π΅Ρ‚ΠΊΠΎΠΌΠΎΡ€Π° прСтставуваат ΠΏΡ€Π΅Π΄ΠΈΠΊΡ‚ΠΈΠ²Π½ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΈ Π·Π° Π°Ρ‚Ρ€ΠΈΡ˜Π°Π»Π½Π° Ρ„ΠΈΠ±Ρ€ΠΈΠ»Π°Ρ†ΠΈΡ˜Π° Π²ΠΎ постопСративниот ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ ΠΏΠΎ Π°ΠΎΡ€Ρ‚ΠΎ-ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Π° бајпас ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΡ˜Π°
    corecore